MedTrace Logo

Clinical Trial on Pharmacokinetic and Tolerability of AP701

NCT04708795 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-03-10

No results posted yet for this study

Summary

This study aims to investigate the uptake of AP701, a preparation from cannabis flowers, into the bloodstream after in single administration in healthy volunteers.

Conditions

  • Pharmacokinetic
  • Tolerability
  • Safety

Interventions

DRUG

AP701

Preparation of Cannabis flowers (Cannabis flos)

Sponsors & Collaborators

  • CannaXan GmbH

    lead INDUSTRY

Principal Investigators

  • Stefan Lorenzl, PhD · Phase I Unit of CannaXan GmbH

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-11
Primary Completion
2021-03-07
Completion
2021-03-07

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708795 on ClinicalTrials.gov